Ustekinumab is a human interleukin-12 and -23 antagonist approved for the treatment of Crohn’s disease. touchIMMUNOLOGY were delighted to talk with Dr. Lorenzo Bertani (University of Pisa, Pisa, Italy) to discuss the rationale, methodology and findings from his study investiagting whether baseline IL-23 serum levels could predict therapeutic response to ustekinumab.
The abstract entitled ‘BASELINE IL-23 SERUM LEVELS PREDICT THERAPEUTIC RESPONSE TO USTEKINUMAB THERAPY IN CROHN’S DISEASE. A PROSPECTIVE STUDY’ was presented at UEG Week, October 8 – 11, 2022.
- What has been the impact of ustekinumab on the treatment of Crohn’s disease and what are its limitations? (0:16)
- What was the rationale for the study you are presenting? (1:01)
- What were the methodology and clinical endpoints of the study? (1:55)
- What factors were found to predict therapeutic response to ustekinumab? (3:01)
- What questions remain unanswered, and what future studies are planned? (4:11)
Disclosures: Lorenzo Bertani has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!